Class summary at a glance.

Every drug in the Iron Chelator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $143.8Mcombined across class
Total Rx claims: 36K8K unique beneficiaries
Generic mfrs (active): 24across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Deferiprone

Brand: FERRIPROX · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2011-11-25

3 generic mfrs 177 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $83.8M

Class share

58%

of class CY24 spend

View profile →

Deferasirox

Brand: Deferasorox · 31K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 2005-11-30

17 generic mfrs 1497 plans require PA

Low NADAC$0.875

→

Avg plan cost$1.28

Part D spend $59.7M 1× spread, current vs floor

Class share

42%

of class CY24 spend

View profile →

Deferoxamine

Brand: Deferoxamine · 762 Part D claims (CY24) · 101 beneficiaries · First FDA approval: 1968-04-02

4 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $224178

Class share

of class CY24 spend

View profile →

Deferasirox Oral

— Part D claims (CY24) · First FDA approval: 2020-07-16

Brand-only (no generics) 525 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.